Fundamental Analysis of IDEXX Laboratories Inc - Growth / Value Index
IDXX - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.481
Book Value in last 3 years is trending up
Tsr Value Index - Poor Score of 28.12
Price to Earning Ratio is 47.75 and EV to EBITDA is 36.83 suggesting that it is very expensive
Price to Book Ratio of 106.44 suggesting that it is very expensive
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 48.53 | 49.77 | -20.23 % | |
Price to Book | 53.13 | 28.33 | 132.95 % | 26.80 |
Price to Sales | 11.29 | 11.49 | -8.70 % | |
Enterprise Value to EBITDA Multiple | 36.40 | 38.78 | -8.80 % |
IDXX - Profitability Highlights
Profitability Analysis
Piotroski F Score - Excellent Value of 8.0
Excellent Net Margin for last 3 years
Over the last 3 years, the company has achieved Incredible Return on Assets
Strong Return On Capital Employed of 33.82
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 79.34%
During the past twelve months, the company has given a strong Return On Asset of 37.25%
All key Trailing Twelve Months Margin growing by 15 %
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Good Net Margin of 23.08% is achieved by the company
Very Low Dividend Yield of 0.730 %
Low Earning Yield of 2.09 %
EPS decline for last four quarters
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 68.93 | 56.92 | -48.97 % | 15.02 |
Return On Asset | 33.20 | 25.92 | -37.20 % | 7.02 |
Net Profit Margin | 23.26 | 23.08 | 14.46 % | 24.44 |
Operating Profit Margin | 29.95 | 29.97 | 12.28 % | 31.01 |
EBITDA Margin | 30.87 | 29.97 | -0.257 % | 34.57 |
Highlights
Market Cap | 41361.37 M |
Enterprise Value | 41855.32 M |
Price/Book TTM | 53.13 |
Outstanding Share | 82587.30 K |
Float/ Outstanding Share | 98.91% |
Dividend Yield | 0.730 % |
Share Holding
Guru Numbers
Price/Graham No | 7.82 |
Peter Lynch Ratio | 0.523 |
Piotroski F Score | 8.00 |
Altman Z Score | 18.20 |
Sloan Ratio | -0.0189 |
Peter Lynch Fair Value | 142.09 |
IDXX - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Poor Score of 34.14
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 3724.85 M | 8.72 % | 6.93 % |
Gross Profit | 2240.07 M | 9.26 % | 12.72 % |
EBITDA | 1150.02 M | 8.44 % | 35.87 % |
Net Profit | 866567 K | 24.44 % | 21.11 % |
EPS | 10.32 | 25.36 % | NA |
IDXX - Stability Highlights
Stability Analysis
Altman Z Score of 17.72 suggests good Stability
Debt to equity ratio has decreased and is lowest in last three years
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0.639 | -49.48 % | 0.615 |
Cash Ratio | 0.477 | 423.82 % | |
Quick Ratio | 1.17 | 97.37 % | 1.16 |
Shareholders Equity | 45.54 | 23.08 % | |
Debt to EBITDA | 0.864 | 13.61 % |
Historical Valuation Ratios of IDEXX Laboratories Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of IDEXX Laboratories Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of IDEXX Laboratories Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of IDEXX Laboratories Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)